The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | Future improvements in developing CLL therapy
While the treatment landscape of chronic lymphocytic lymphoma (CLL) has been exciting with many breakthrough therapies, there are still key areas for improvement. Speaking from the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from the University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK stresses the importance of moving novel therapies rapidly into Phase III trials if they have shown promising results. Prof. Hillmen also talks about banking samples and translational research to improve understanding and refine treatment.
